Today announced that its Board of Directors has unanimously rejected Frontline’s April 25 proposal to acquire all of the outstanding shares of common stock of DHT at a ratio of 0.8 Frontline shares for each DHT share.
The Board’s response is contained in a letter to Robert Hvide Macleod, Principal Executive Officer of Frontline, which can be accessed through the link below.
The offer made in April was identical to an offer made in February, which DHT rejected as well claiming that the offer undervalued the company significantly.
Full Content: Globe Newswire
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
